
FOR IMMEDIATE RELEASE

**License, Distribution and Supply Agreement to market
Neridronic Acid in China, Hong Kong, Macau and Taiwan**

Hong Kong, 11 April 2014 - Lee's Pharmaceutical Holdings Limited ("the Group" or "Lee's") (Main Board Stock Code: 0950; Website: www.leespharm.com) and Abiogen Pharma S.p.A. of Pisa, Italy today jointly announced the signing of an agreement for License, Distribution and Supply for marketing of **Attila® (Neridronic Acid)** throughout China, Hong Kong, Macau and Taiwan.

Under the term of agreement, Lee's granted an exclusive license and right for registering, importing, marketing, distributing and selling the Sodium Neridronate finished products (25mg/2ml, solution for injection and 100mg/8ml, concentrate for solution for infusion) in the territory, for the two orphan/rare disease indications as Osteogenesis Imperfecta and Complex Regional Pain Syndrome (also known as Algodistrophy).

Neridronate is the only therapeutic agent approved in the world for orphan diseases: Osteogenesis Imperfecta (OI, Brittle bone disease) and Complex Regional Pain Syndrome (CRPS). Neridronic acid is registered in Italy and used by patients in 32 European countries under the trade name of Nerixia®. Neridronate consistently showed superior safety profile in long-term use and is highly tolerated by adults and pediatric population. It is the only bisphosphonate indicated for use in neonates and children.

"We're extremely pleased with our partnership with Abiogen Pharma, and excited about the opportunity to work on Neridronate in our territory," said Dr. Benjamin Li, Chief Executive Officer. "This is the fourth orphan drug we have licensed-in and it again demonstrates our commitment to rare diseases in China."

Dr. Massimo Di Martino, President & CEO of Abiogen Pharma said "I am particularly happy to see that Neridronate could cross political and geographic barriers to benefit the patients. Our partnership with Leespharm will help patients in China and Taiwan to fight critical rare diseases for which there is no other treatment option available."

About Abiogen Pharma

Abiogen Pharma is a privately owned specialist pharmaceutical company focused on bone metabolism and some rare diseases. The Company was founded in 1997 as a spin-off of Istituto Gentili. Abiogen employs about 330 people with its headquarters in Pisa, Italy. The team of R&D of Abiogen Pharma had developed and continues to develop several bisphosphonates, including ethidronate, alendronate, clodronate and neridronate. For more information, please visit www.abiogen.it.



FOR IMMEDIATE RELEASE

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.

About Attila® (sodium neridronate)

Attila® is an aminobisphosphonate developed and owned by Abiogen Pharma, Pisa. The Anti-resorptive activity leads to decrease in bone turnover, which is the basis for use of this drug in Osteogenesis imperfecta. It is the only bisphosphonate approved for use in infants, children and adults. The product obtained first registration in Italy in 2002 as Nerixia®. Neridronate is the only drug in the world officially approved for the treatment of Osteogenesis imperfecta and Complex Regional Pain type 1, also known as Algodystrophy.

About Osteogenesis Imperfecta

Osteogenesis imperfecta (OI) is a genetic disorder caused by mutation of the COL1 A1 or A2 genes, characterized by fragile bones that break easily and low bone mass which lead to associated deformities and pain. The disease is also known as brittle bone disease, glass bone disease, China doll etc. OI patients typically manifest blue sclera, brittle teeth (dentinogenesis imperfecta) and presence of wormian bones on skull radiographs. OI is a recognized rare disease with a prevalence of 1 in 10,000 live births in Europe.

About Complex regional pain syndrome type 1 (CRPS1).

Complex regional pain syndrome is a condition characterized by persistent long term disabling pain, often starting in a peripheral limb which may impair the ability to move and perform daily activities. Although the condition usually develops after an injury, the pain experienced is greater than what would normally be expected from the injury. The skin of the affected area can become very sensitive and even a simple touch can cause intense unbearable pain. As the disease progresses, it often spreads beyond the affected limb. CRPS1 is a recognized rare disease with a prevalence of about 3 in 10,000 people in Europe. The published prevalence rate of CRPS1 in China is lower than in Europe.

FOR IMMEDIATE RELEASE

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com

Mithu Sen

Tel: +39 050 3154 273

Email: mithu.sen@abiogen.it

Fabrizio Nannipieri

Tel: +39 050 3154 289

Email: fabrizio.nannipieri@abiogen.it